Kcentra 1,000 unit vials
Ended Awarded
- Contract number
- SPE2DR26FQJT9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,640
Award facts
- Contract value 100% obligated
- $9,639.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $9,639.84 to DMS Pharmaceutical Group Inc. for 1,000 unit vials of Kcentra on November 13, 2025, with an ultimate completion date of December 5, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without any set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order falls under the broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion DLA acquisition strategy that positions qualified prime vendors as critical suppliers of pharmaceuticals and medical consumables to support Department of Defense military healthcare facilities worldwide.
This award represents one of numerous delivery orders issued to DMS Pharmaceutical Group under its single-award Indefinite Delivery Contract with the DLA, designated as contract SPE2DR, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and a completion date of December 31, 2036. The IDC authorizes the DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, vaccines, and medical consumables. DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and established performance across multiple therapeutic categories, positioning it as a reliable supplier within the federal pharmaceutical supply chain for military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQJT9?
SPE2DR26FQJT9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FQJT9 worth?
The government has obligated $9,640 on SPE2DR26FQJT9.
Is contract SPE2DR26FQJT9 an order under another contract?
Yes. SPE2DR26FQJT9 is a delivery order under SPE2DR25D9135, an indefinite delivery contract.
Was contract SPE2DR26FQJT9 competed?
The extent of competition for SPE2DR26FQJT9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award